Ximedica

Ximedica is a full-service design and development firm with an exclusive focus on medical devices, combination products and consumer health. Its drug delivery expertise includes topical, transmucosal, inhalation, and injection. It is ISO 13485:2016 certified and US FDA registered.

Headquarters
Ximedica
55, Dupont Dr
Providence
RI 02907
United States

Phone / Contact

T: +1 401 330 3163

Connect

Ximedica is a full-service design and development firm with an exclusive focus on medical devices, combination products and consumer health. The company’s approach includes: research, strategy and concept generation; concept requirements development; detailed design development; design verification; process validation, manufacturing transfer & design validation; and production and commercial support.

It’s main areas of activity are med tech, diagnostics, drug delivery systems, digital, and manufacturing. Its drug delivery expertise includes topical, transmucosal, inhalation, and injection. It is ISO 13485:2016 certified and US FDA registered.

Ximedica was founded in 1985, its headquarters are in Providence, RI, US, and it has offices in Hong Kong, Minneapolis (MN, US), and San Francisco (CA, US). The company is privately held, and in November 2014, Boston MA, US-based private equity firm SV LifeSciences acquired a majority stake.

Articles by Ximedica

HOW DIGITAL TECHNOLOGY CAN TRANSFORM CLINICAL TRIALS

Sheila Trgovac and Rebecca Ford suggest that now is the time for innovation in clinical trials – using a patient-centric approach whilst leveraging digital solutions to create a digital clinical trial ecosystem.

How the current pandemic will shape healthcare innovation for the next decade

In its COVID-19 announcement, Ximedica has confirmed that its manufacturing facility remains open under the “essential service” classification and that is focusing on US national efforts to help address the challenges surrounding ventilator and PPE supplies. It also highlighted its core strength in engineering, with more than 200 engineers who have established several highly effective means of remote collaboration.

THE CHALLENGES OF A CHANGING MARKET & THE BENEFITS OF DEVELOPMENT FLEXIBILITY

David Fink and Sheila Trgovac describe how adopting a flexible development model in mid-to-late development brings benefits through to commercialisation, especially in the context of a changing market.

ASSESSING USABILITY EARLY FOR OPTIMAL INJECTION PEN DESIGN

David Fink and Stefan Gaul use the example of Haselmeier’s D-Flex system to explain why it is important to undertake a full use-related risk analysis for injection pen products to assess their usability and identify any risks, highlighting the importance of considering usability right from the start.

THE BIGGEST MISTAKES COMPANIES MAKE COMMERCIALISING DRUG DELIVERY – AND WHAT TO DO ABOUT THEM

It is difficult to successfully scale-up a product to industrial production and launch, but it is much harder if design fundamentals are not adhered to. Beth Blackburn details the need for setting down requirements early in device development in order to avoid inadvertently undermining a product’s successful commercialisation.

Top